US20020173643A1
(en)
*
|
1995-04-14 |
2002-11-21 |
Kappes John C. |
Fusion protein delivery system and uses thereof
|
AU732703B2
(en)
*
|
1996-11-20 |
2001-04-26 |
Crucell Holland B.V. |
An improved method for the production and purification of adenoviral vectors
|
EP2325299A3
(en)
*
|
1997-09-05 |
2011-10-05 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of recombinant AAV vectors
|
US6566118B1
(en)
|
1997-09-05 |
2003-05-20 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US6989264B2
(en)
|
1997-09-05 |
2006-01-24 |
Targeted Genetics Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
US7033595B1
(en)
|
1998-08-04 |
2006-04-25 |
Purdue Research Foundation |
Pseudotyped retroviruses and stable cell lines for their production
|
EP1930418B1
(en)
|
1998-09-04 |
2015-04-08 |
Genzyme Corporation |
Methods for generating high titer helper-free preparations of released recombinant AAV vectors
|
PT1109892E
(pt)
*
|
1998-09-04 |
2009-02-17 |
Targeted Genetics Corp |
Métodos para produzir preparações de vectores de aav recombinantes libertados, de título elevado, isentas de vírus auxiliares
|
EP1203016A2
(en)
*
|
1999-08-09 |
2002-05-08 |
Incyte Genomics, Inc. |
Proteases and protease inhibitors
|
EP1210429A2
(en)
*
|
1999-09-10 |
2002-06-05 |
Incyte Genomics, Inc. |
Apoptosis proteins
|
US6790614B1
(en)
|
1999-11-19 |
2004-09-14 |
Novartis Ag |
Selectable cell surface marker genes
|
EP1282727A1
(en)
|
2000-02-25 |
2003-02-12 |
Biofocus Discovery Limited |
Methods for identifying candidate polynucleotide molecules encoding a protease
|
AU2001240019A1
(en)
*
|
2000-03-03 |
2001-09-17 |
Incyte Genomics, Inc. |
G-protein coupled receptors
|
US6849454B2
(en)
|
2000-03-07 |
2005-02-01 |
St. Jude Children's Research Hospital |
Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles
|
AU2001266975A1
(en)
|
2000-06-16 |
2002-01-02 |
Incyte Genomics, Inc. |
G-protein coupled receptors
|
US7608704B2
(en)
|
2000-11-08 |
2009-10-27 |
Incyte Corporation |
Secreted proteins
|
US7122182B2
(en)
*
|
2001-05-11 |
2006-10-17 |
Wellstat Biologics Corporation |
Oncolytic virus therapy
|
WO2003070902A2
(en)
*
|
2002-02-20 |
2003-08-28 |
Incyte Corporation |
Receptors and membrane-associated proteins
|
AU2003237374A1
(en)
*
|
2002-06-04 |
2003-12-19 |
Centers For Disease Control And Prevention |
Improved pseudotyped retroviruses
|
US20040009158A1
(en)
*
|
2002-07-11 |
2004-01-15 |
Washington University |
Promotion of neovascularization using bone marrow-derived endothelial-progenitor cells
|
AU2003265431A1
(en)
*
|
2002-08-13 |
2004-02-25 |
Incyte Corporation |
Cell adhesion and extracellular matrix proteins
|
US20070219353A1
(en)
*
|
2002-09-03 |
2007-09-20 |
Incyte Corporation |
Immune Response Associated Proteins
|
AU2003279829A1
(en)
*
|
2002-10-04 |
2004-05-04 |
Incyte Corp |
Protein modification and maintenance molecules
|
US20050164275A1
(en)
*
|
2002-10-18 |
2005-07-28 |
Incyte Corporation |
Phosphodiesterases
|
WO2004044166A2
(en)
*
|
2002-11-12 |
2004-05-27 |
Incyte Corporation |
Carbohydrate-associated proteins
|
WO2004044165A2
(en)
*
|
2002-11-13 |
2004-05-27 |
Incyte Corporation |
Lipid-associated proteins
|
US20070009516A1
(en)
*
|
2002-11-26 |
2007-01-11 |
Tran Uyen K |
Immune response-associated proteins
|
WO2004098539A2
(en)
|
2003-04-30 |
2004-11-18 |
Incyte Corporation |
Kinases and phosphatases
|
CA2545938A1
(en)
*
|
2003-11-12 |
2005-05-26 |
Universite Laval |
High-titer retroviral packaging cells
|
TR201900968T4
(tr)
|
2004-09-24 |
2019-02-21 |
Mesoblast Inc |
Multipotansiyel genleşmiş mezenkimal prekürsör hücre soyu (memp) ve bunların kullanımı.
|
ES2645012T3
(es)
|
2004-09-24 |
2017-12-01 |
Mesoblast, Inc. |
Método para potenciar la proliferación y/o supervivencia de las células precursoras mesenquimales (MPC)
|
US8325826B2
(en)
*
|
2005-03-09 |
2012-12-04 |
Qualcomm Incorporated |
Methods and apparatus for transmitting signals facilitating antenna control
|
US7826807B2
(en)
*
|
2005-03-09 |
2010-11-02 |
Qualcomm Incorporated |
Methods and apparatus for antenna control in a wireless terminal
|
EP2399991B1
(en)
|
2005-04-12 |
2017-09-27 |
Mesoblast, Inc. |
Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
|
WO2006130855A2
(en)
*
|
2005-06-01 |
2006-12-07 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
US20090227032A1
(en)
*
|
2005-12-13 |
2009-09-10 |
Kyoto University |
Nuclear reprogramming factor and induced pluripotent stem cells
|
US8129187B2
(en)
*
|
2005-12-13 |
2012-03-06 |
Kyoto University |
Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
|
US8278104B2
(en)
*
|
2005-12-13 |
2012-10-02 |
Kyoto University |
Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
|
EP2206724A1
(en)
*
|
2005-12-13 |
2010-07-14 |
Kyoto University |
Nuclear reprogramming factor
|
WO2007124573A1
(en)
*
|
2006-04-28 |
2007-11-08 |
Universite Laval |
High-titer retroviral packaging cells
|
US8225186B2
(en)
|
2006-07-14 |
2012-07-17 |
Qualcomm Incorporated |
Ecoding and decoding methods and apparatus for use in a wireless communication system
|
US7724853B2
(en)
*
|
2006-07-14 |
2010-05-25 |
Qualcomm Incorporated |
Enabling mobile switched antennas
|
US7720485B2
(en)
*
|
2006-07-14 |
2010-05-18 |
Qualcomm Incorporated |
Methods and apparatus related to assignment in a wireless communications system
|
PL2048955T3
(pl)
*
|
2006-07-21 |
2013-11-29 |
California Inst Of Techn |
Nakierowane dostarczanie genu dla szczepienia komórek dendrytycznych
|
ES2569365T3
(es)
|
2006-11-29 |
2016-05-10 |
Nationwide Children's Hospital |
Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
|
EP2155862A2
(en)
|
2007-05-04 |
2010-02-24 |
Whitehead Institute For Biomedical Research |
Ex vivo expansion of human hematopoietic stem cells
|
US9213999B2
(en)
*
|
2007-06-15 |
2015-12-15 |
Kyoto University |
Providing iPSCs to a customer
|
JP2008307007A
(ja)
*
|
2007-06-15 |
2008-12-25 |
Bayer Schering Pharma Ag |
出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
|
EP3424514B1
(en)
|
2007-08-06 |
2022-05-11 |
Mesoblast, Inc. |
Tnap+ mesenchymal precursor cells for use in treating connective tissue diseases
|
TWI325401B
(en)
*
|
2007-12-17 |
2010-06-01 |
Duen Gang Mou |
Vessel structure
|
EP2268809B1
(en)
|
2008-05-02 |
2019-02-06 |
Kyoto University |
Method of nuclear reprogramming
|
JP5826629B2
(ja)
|
2008-08-18 |
2015-12-02 |
メゾブラスト,インコーポレーテッド |
モノクローナル抗体stro−4
|
US9415121B2
(en)
|
2008-12-19 |
2016-08-16 |
Nationwide Children's Hospital |
Delivery of MECP2 polynucleotide using recombinant AAV9
|
US11219696B2
(en)
|
2008-12-19 |
2022-01-11 |
Nationwide Children's Hospital |
Delivery of polynucleotides using recombinant AAV9
|
NZ597804A
(en)
|
2009-07-24 |
2013-10-25 |
Immune Design Corp |
Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
|
CN108744262A
(zh)
|
2010-11-23 |
2018-11-06 |
普莱萨格生命科学公司 |
用于实体递送的治疗方法和组合物
|
US10196636B2
(en)
|
2011-04-21 |
2019-02-05 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of myotilin
|
ES2702496T3
(es)
|
2011-04-21 |
2019-03-01 |
Nationwide Childrens Hospital Inc |
Productos de virus recombinante y procedimientos para la inhibición de la expresión de la miotilina
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
WO2013016352A1
(en)
|
2011-07-25 |
2013-01-31 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
WO2013078316A1
(en)
|
2011-11-23 |
2013-05-30 |
Nationwide Children's Hospital, Inc. |
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
|
US8323662B1
(en)
|
2012-03-30 |
2012-12-04 |
Immune Design Corp. |
Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
|
US9713635B2
(en)
|
2012-03-30 |
2017-07-25 |
Immune Design Corp. |
Materials and methods for producing improved lentiviral vector particles
|
EP2831095B1
(en)
|
2012-03-30 |
2018-11-28 |
Immune Design Corp. |
Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
|
JP6314138B2
(ja)
|
2012-08-01 |
2018-04-18 |
ネイションワイド チルドレンズ ホスピタル |
組換えアデノ随伴ウイルス9の髄腔内送達
|
JP6901823B2
(ja)
|
2012-08-01 |
2021-07-14 |
ユナイテッド セラピューティクス コーポレイション |
間葉系幹細胞による肺動脈性高血圧症の処置
|
CA2880811C
(en)
|
2012-08-01 |
2021-12-07 |
United Therapeutics Corporation |
Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
|
JP2015529685A
(ja)
|
2012-09-17 |
2015-10-08 |
ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルThe Research Institute Atnationwide Children’S Hospital |
筋萎縮性側索硬化症の処置のための組成物および方法
|
ES2963968T3
(es)
|
2013-01-09 |
2024-04-03 |
United Therapeutics Corp |
Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas
|
JP6461917B2
(ja)
|
2013-04-20 |
2019-01-30 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
エクソン2標的U7snRNAポリヌクレオチド構築物の組換えアデノ随伴ウイルスによる送達
|
WO2014183071A2
(en)
|
2013-05-10 |
2014-11-13 |
Whitehead Institute For Biomedical Research |
In vitro production of red blood cells with sortaggable proteins
|
RS63942B1
(sr)
|
2013-08-27 |
2023-02-28 |
Res Inst Nationwide Childrens Hospital |
Proizvodi i postupci za lečenje amiotrofične lateralne skleroze
|
EP3065784A4
(en)
|
2013-11-05 |
2017-05-10 |
The Research Institute at Nationwide Children's Hospital |
COMPOSITIONS AND METHODS FOR INHIBITING NF- kB AND SOD-1 TO TREAT AMYOTROPHIC LATERAL SCLEROSIS
|
WO2015142984A1
(en)
|
2014-03-18 |
2015-09-24 |
Washington University |
Methods and compositions for red-shifted chromophore substitution for optogenetic applications
|
WO2015162302A2
(en)
*
|
2014-04-25 |
2015-10-29 |
Genethon |
Treatment of hyperbilirubinemia
|
JP6986444B2
(ja)
|
2014-08-09 |
2021-12-22 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Dmd遺伝子のエクソン5内の内部リボソーム進入部位を活性化するための方法及び材料
|
US10842886B2
(en)
|
2014-10-10 |
2020-11-24 |
Research Institute At Nationwide Children's Hospital |
Guided injections for AAV gene transfer to muscle
|
CA2966884A1
(en)
|
2014-11-05 |
2016-05-12 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for producing recombinant viruses in eukaryotic microalgae
|
MA41451A
(fr)
|
2015-02-04 |
2017-12-12 |
Univ Washington |
Constructions anti-tau
|
SG11201706767RA
(en)
|
2015-02-23 |
2017-09-28 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
US10755078B2
(en)
*
|
2015-04-10 |
2020-08-25 |
President And Fellows Of Harvard College |
Methods and devices for live cell imaging analysis
|
US10017832B2
(en)
|
2015-08-25 |
2018-07-10 |
Washington University |
Compositions and methods for site specific recombination at asymmetric sites
|
CA2998636A1
(en)
|
2015-09-17 |
2017-03-23 |
Research Institute At Nationwide Children's Hospital |
Methods and materials for galgt2 gene therapy
|
JP2018532402A
(ja)
|
2015-09-24 |
2018-11-08 |
クリスパー セラピューティクス アーゲー |
Rnaプログラム可能エンドヌクレアーゼの新規のファミリーならびにゲノム編集および他の適用におけるそれらの使用
|
JP2019507579A
(ja)
|
2015-10-28 |
2019-03-22 |
クリスパー セラピューティクス アーゲー |
デュシェンヌ型筋ジストロフィーの処置のための材料および方法
|
EP3371305A1
(en)
|
2015-11-06 |
2018-09-12 |
Crispr Therapeutics AG |
Materials and methods for treatment of glycogen storage disease type 1a
|
JP7418957B2
(ja)
|
2015-11-16 |
2024-01-22 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法
|
CA3006618A1
(en)
|
2015-12-01 |
2017-06-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of alpha-1 antitrypsin deficiency
|
AU2016370590B2
(en)
|
2015-12-14 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of Crigler-Najjar syndrome
|
BR112018012894A2
(pt)
|
2015-12-23 |
2018-12-04 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de esclerose lateral amiotrófica e/ou degeneração lobular frontotemporal
|
US11938193B2
(en)
|
2016-01-08 |
2024-03-26 |
Washington University |
Compositions comprising chemerin and methods of use thereof
|
WO2017134529A1
(en)
|
2016-02-02 |
2017-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
EP3416689B1
(en)
|
2016-02-18 |
2023-01-18 |
CRISPR Therapeutics AG |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
WO2017147509A1
(en)
|
2016-02-25 |
2017-08-31 |
Marco Colonna |
Compositions comprising trem2 and methods of use thereof
|
EP3420109A4
(en)
|
2016-02-26 |
2019-11-06 |
Research Institute at Nationwide Children's Hospital |
RECOMBINANT VIRUS PRODUCTS AND METHOD OF INDUCING DUX4 EXON SKIPPING
|
EP3429632B1
(en)
|
2016-03-16 |
2023-01-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of hereditary haemochromatosis
|
CN109714954A
(zh)
|
2016-04-02 |
2019-05-03 |
全国儿童医院研究所 |
用于组织特异性表达的修饰的u6启动子系统
|
RS65490B1
(sr)
|
2016-04-15 |
2024-05-31 |
Res Inst Nationwide Childrens Hospital |
Vektor adeno-asociranog virusa za isporuku β-sarkoglikana i mikrorna-29 i tretman mišićne distrofije
|
MA45477A
(fr)
|
2016-04-15 |
2019-02-20 |
Res Inst Nationwide Childrens Hospital |
Administration à vecteurs de virus adéno-associé de microarn-29 et micro-dystrophine pour traiter la dystrophie musculaire
|
BR112018071321A2
(pt)
|
2016-04-18 |
2019-02-26 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de hemoglobinopatias
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
EP3478313B1
(en)
|
2016-06-29 |
2022-05-04 |
CRISPR Therapeutics AG |
Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders
|
WO2018002783A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
WO2018002812A1
(en)
|
2016-06-29 |
2018-01-04 |
Crispr Therapeutics Ag |
Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders
|
JP7305534B2
(ja)
|
2016-07-06 |
2023-07-10 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
疼痛関連障害を処置するための物質及び方法
|
JP2019520079A
(ja)
|
2016-07-06 |
2019-07-18 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
疼痛関連障害を処置するための物質及び方法
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
CA3041514A1
(en)
|
2016-10-24 |
2018-05-03 |
United Therapeutics Corporation |
Enhancement of msc immunomodulatory properties by treprostinil
|
JP7106534B2
(ja)
|
2016-11-17 |
2022-07-26 |
ネイションワイド チルドレンズ ホスピタル, インコーポレイテッド |
メチル-cpg結合タンパク質2をコードする組換えアデノ随伴ウイルスの髄腔内送達
|
CN110191955B
(zh)
|
2016-12-13 |
2024-05-31 |
西雅图儿童医院(Dba西雅图儿童研究所) |
在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
|
EP3585899A1
(en)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
|
WO2018154439A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
|
CN110662838B
(zh)
|
2017-02-22 |
2024-05-28 |
克里斯珀医疗股份公司 |
用于基因编辑的组合物和方法
|
EP3585900B1
(en)
|
2017-02-22 |
2022-12-21 |
CRISPR Therapeutics AG |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
MA47800A
(fr)
|
2017-03-17 |
2020-01-22 |
Univ Newcastle |
Délivrance par vecteur viral adéno-associé d'un fragment de micro-dystrophine pour traiter la dystrophie musculaire
|
MA52112B1
(fr)
|
2017-03-17 |
2023-08-31 |
Res Inst Nationwide Childrens Hospital |
Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique du muscle pour traiter la dystrophie musculaire
|
US11622977B2
(en)
|
2017-05-12 |
2023-04-11 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
CN111065741A
(zh)
|
2017-07-08 |
2020-04-24 |
吉尼松公司 |
脊髓性肌萎缩症的治疗
|
SG11202003464VA
(en)
|
2017-10-17 |
2020-05-28 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing for hemophilia a
|
JP7213238B2
(ja)
|
2017-10-18 |
2023-01-26 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
筋ジストロフィーを治療するための筋特異的マイクロジストロフィンのアデノ随伴ウイルスベクター送達
|
EP3697916A4
(en)
|
2017-10-20 |
2021-08-11 |
Research Institute at Nationwide Children's Hospital |
METHODS AND MATERIALS FOR NT-3 GENE THERAPY
|
MA50849A
(fr)
|
2017-10-26 |
2020-09-02 |
Vertex Pharma |
Substances et procédés pour le traitement d'hémoglobinopathies
|
SG11202004406VA
(en)
|
2017-11-08 |
2020-06-29 |
Avexis Inc |
Means and method for preparing viral vectors and uses of same
|
US20210363521A1
(en)
|
2017-11-09 |
2021-11-25 |
Vertex Pharmaceuticals Incorporated |
CRISPR/CAS Systems For Treatment of DMD
|
CN111727251A
(zh)
|
2017-11-21 |
2020-09-29 |
克里斯珀医疗股份公司 |
用于治疗常染色体显性色素性视网膜炎的材料和方法
|
US11578323B2
(en)
|
2017-12-14 |
2023-02-14 |
Bayer Healthcare Llc |
RNA-programmable endonuclease systems and their use in genome editing and other applications
|
EP3728594A1
(en)
|
2017-12-21 |
2020-10-28 |
CRISPR Therapeutics AG |
Materials and methods for treatment of usher syndrome type 2a
|
EP3728595A1
(en)
|
2017-12-21 |
2020-10-28 |
CRISPR Therapeutics AG |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
WO2019140330A1
(en)
|
2018-01-12 |
2019-07-18 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for gene editing by targeting transferrin
|
US11268077B2
(en)
|
2018-02-05 |
2022-03-08 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
MA51787A
(fr)
|
2018-02-05 |
2020-12-16 |
Vertex Pharma |
Substances et méthodes de traitement d'hémoglobinopathies
|
MA51869A
(fr)
|
2018-02-16 |
2020-12-23 |
Bayer Healthcare Llc |
Compositions et méthodes pour l'édition génique par ciblage du fibrinogène-alpha
|
US20210054353A1
(en)
|
2018-03-19 |
2021-02-25 |
Crispr Therapeutics Ag |
Novel rna-programmable endonuclease systems and uses thereof
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
SG11202007874XA
(en)
|
2018-04-27 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Rapamycin resistant cells
|
JP7478675B2
(ja)
|
2018-06-08 |
2024-05-07 |
ノバルティス アーゲー |
薬物製品の効力を測定するための細胞ベースアッセイ
|
GB201809588D0
(en)
|
2018-06-12 |
2018-07-25 |
Univ Bristol |
Materials and methods for modulating intraocular and intracranial pressure
|
BR112020025995A2
(pt)
|
2018-06-18 |
2021-03-23 |
Research Institute At Nationwide Children's Hospital |
administração de microdistrofina músculo-específica por vetor de vírus adeno-associado para tratar a distrofia muscular
|
CA3104471A1
(en)
|
2018-06-18 |
2019-12-26 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating dystroglycanopathies and laminin-deficient muscular dystrophies
|
AU2019295779A1
(en)
|
2018-06-29 |
2021-01-28 |
Research Institute At Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
|
US20210324417A1
(en)
|
2018-08-29 |
2021-10-21 |
Research Institute At Nationwide Children's Hospital |
Products and methods for inhibition of expression of mutant gars protein
|
BR112021007403A2
(pt)
|
2018-10-17 |
2021-12-07 |
Bayer Healthcare Llc |
Composições e métodos para entrega de transgenes
|
MX2021006359A
(es)
|
2018-11-30 |
2021-08-11 |
Novartis Ag |
Vectores virales de vaa y sus usos.
|
CA3122319A1
(en)
|
2018-12-21 |
2020-06-25 |
Genethon |
Expression cassettes for gene therapy vectors
|
AU2019419494A1
(en)
|
2018-12-31 |
2021-07-15 |
Research Institute At Nationwide Children's Hospital |
DUX4 RNA silencing using RNA targeting CRISPR-Cas13b
|
CA3127801A1
(en)
|
2019-02-04 |
2020-08-13 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery of cln6 polynucleotide
|
SG11202107986YA
(en)
|
2019-02-04 |
2021-08-30 |
Res Inst Nationwide Childrens Hospital |
Adeno-associated virus delivery of cln3 polynucleotide
|
WO2020168362A1
(en)
|
2019-02-15 |
2020-08-20 |
Crispr Therapeutics Ag |
Gene editing for hemophilia a with improved factor viii expression
|
EP3930765A1
(en)
|
2019-02-26 |
2022-01-05 |
Research Institute at Nationwide Children's Hospital |
Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy
|
EP3937963A2
(en)
|
2019-03-12 |
2022-01-19 |
CRISPR Therapeutics AG |
Novel high fidelity rna-programmable endonuclease systems and uses thereof
|
EP3955969A1
(en)
|
2019-04-15 |
2022-02-23 |
Sanford Research |
Gene therapy for treating or preventing visual effects in batten disease
|
US20210047649A1
(en)
|
2019-05-08 |
2021-02-18 |
Vertex Pharmaceuticals Incorporated |
Crispr/cas all-in-two vector systems for treatment of dmd
|
CA3141017A1
(en)
|
2019-05-17 |
2020-11-26 |
Research Institute At Nationwide Children's Hospital |
Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme
|
EP3990636A1
(en)
|
2019-06-28 |
2022-05-04 |
CRISPR Therapeutics AG |
Materials and methods for controlling gene editing
|
KR20220035937A
(ko)
|
2019-07-25 |
2022-03-22 |
노파르티스 아게 |
조절 가능한 발현 시스템
|
CA3150964A1
(en)
|
2019-08-21 |
2021-02-25 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
|
US20220378945A1
(en)
|
2019-10-18 |
2022-12-01 |
Research Institute At Nationwide Children's Hospital |
Gene therapy targeting cochlear cells
|
JP2022552014A
(ja)
|
2019-10-18 |
2022-12-14 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Irf2bpl遺伝子の変異に関連する障害の治療のための材料および方法
|
EP4061831A1
(en)
|
2019-11-22 |
2022-09-28 |
Research Institute at Nationwide Children's Hospital |
Materials and methods for treatment of disorders associated with the ighmbp2 gene
|
AU2020408225A1
(en)
|
2019-12-20 |
2022-07-14 |
Research Institute At Nationwide Children's Hospital |
Optimized gene therapy for targeting muscle in muscle diseases
|
CA3171959A1
(en)
|
2020-02-18 |
2021-08-26 |
Research Institute At Nationwide Children's Hospital |
Aav-mediated targeting of mirna in the treatment of x-linked disorders
|
CA3174863A1
(en)
|
2020-04-14 |
2021-10-21 |
Ana BUJ BELLO |
Vectors for the treatment of acid ceramidase deficiency
|
AU2021293197A1
(en)
|
2020-06-15 |
2023-02-09 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus vector delivery for muscular dystrophies
|
WO2022018638A1
(en)
|
2020-07-21 |
2022-01-27 |
Crispr Therapeutics Ag |
Genome-editing compositions and methods to modulate faah for treatment of neurological disorders
|
TW202227634A
(zh)
|
2020-09-08 |
2022-07-16 |
美商薩羅塔治療公司 |
表現γ—肌聚醣之腺相關病毒載體之全身性遞送及肌肉失養症之治療
|
WO2022060841A2
(en)
|
2020-09-15 |
2022-03-24 |
Research Institute At Nationwide Children's Hospital |
Aav-mediated homology-independent targeted integration gene editing for correction of diverse dmd mutations in patients with muscular dystrophy
|
CA3194122A1
(en)
|
2020-09-28 |
2022-03-31 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treating muscular dystrophy
|
WO2022070107A1
(en)
|
2020-09-30 |
2022-04-07 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis
|
IL303230A
(en)
|
2020-11-30 |
2023-07-01 |
Res Inst Nationwide Childrens Hospital |
Preparations and methods for the treatment of facial-shoulder-arm muscle atrophy
|
WO2022133246A1
(en)
|
2020-12-17 |
2022-06-23 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
|
EP4284413A1
(en)
|
2021-01-27 |
2023-12-06 |
Research Institute at Nationwide Children's Hospital |
Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d)
|
JP2024505575A
(ja)
|
2021-02-03 |
2024-02-06 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Dux4過剰発現に関連する疾患を治療するための組成物及び方法
|
WO2022170038A1
(en)
|
2021-02-05 |
2022-08-11 |
Amicus Therapeutics, Inc. |
Adeno-associated virus delivery of cln3 polynucleotide
|
EP4301462A1
(en)
|
2021-03-04 |
2024-01-10 |
Research Institute at Nationwide Children's Hospital |
Products and methods for treatment of dystrophin-based myopathies using crispr-cas9 to correct dmd exon duplications
|
CN115427561B
(zh)
|
2021-03-09 |
2024-06-04 |
辉大(上海)生物科技有限公司 |
工程化CRISPR/Cas13系统及其用途
|
JP2024515623A
(ja)
|
2021-04-13 |
2024-04-10 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
髄腔内送達によってピット・ホプキンス症候群を治療するためのメチル-cpg結合タンパク質2をコードする組換えアデノ随伴ウイルス
|
AU2022262420A1
(en)
|
2021-04-23 |
2023-11-16 |
Research Institute At Nationwide Children's Hospital |
Products and methods for treating muscular dystrophy
|
WO2022234295A1
(en)
|
2021-05-07 |
2022-11-10 |
Ucl Business Ltd |
Abca4 genome editing
|
WO2022245675A1
(en)
|
2021-05-17 |
2022-11-24 |
Sarepta Therapeutics, Inc. |
Production of recombinant aav vectors for treating muscular dystrophy
|
EP4108263A3
(en)
|
2021-06-02 |
2023-03-22 |
Research Institute at Nationwide Children's Hospital |
Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
|
EP4101928A1
(en)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Type v rna programmable endonuclease systems
|
AU2022290382A1
(en)
|
2021-06-11 |
2023-11-23 |
Bayer Aktiengesellschaft |
Type v rna programmable endonuclease systems
|
WO2023283962A1
(en)
|
2021-07-16 |
2023-01-19 |
Huigene Therapeutics Co., Ltd. |
Modified aav capsid for gene therapy and methods thereof
|
CN118159656A
(zh)
|
2021-08-11 |
2024-06-07 |
坚固生物科技公司 |
肌营养不良的治疗
|
EP4144841A1
(en)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
|
WO2023042104A1
(en)
|
2021-09-16 |
2023-03-23 |
Novartis Ag |
Novel transcription factors
|
AU2022360382A1
(en)
|
2021-10-07 |
2024-05-09 |
Research Institute At Nationwide Children's Hospital |
Products and methods for myelin protein zero silencing and treating cmt1b disease
|
WO2023060233A1
(en)
|
2021-10-08 |
2023-04-13 |
Amicus Therapeutics, Inc. |
Biomarkers for lysosomal storage diseases
|
JP2023059858A
(ja)
|
2021-10-15 |
2023-04-27 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
|
US20230279431A1
(en)
|
2021-11-30 |
2023-09-07 |
Research Institute At Nationwide Children's Hospital |
Self-Complementary Adeno-Associated Virus Vector and its Use in Treatment of Muscular Dystrophy
|
EP4198134A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Gamma-sarcoglycan gene transfer increase using modified itr sequences
|
EP4198048A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Calpain-3 gene transfer increase using modified itr sequences
|
EP4198046A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Alpha-sarcoglycan gene transfer increase using modified itr sequences
|
EP4198047A1
(en)
|
2021-12-16 |
2023-06-21 |
Genethon |
Fukutin related protein gene transfer increase using modified itr sequences
|
AU2022420596A1
(en)
|
2021-12-21 |
2024-07-11 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of limb girdle muscular dystrophy
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023168400A2
(en)
|
2022-03-03 |
2023-09-07 |
Research Institute At Nationwide Children's Hospital |
Materials and methods for the treatment of eif2b5 mutations and diseases resulting therefrom
|
WO2023196818A1
(en)
|
2022-04-04 |
2023-10-12 |
The Regents Of The University Of California |
Genetic complementation compositions and methods
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
WO2023240177A1
(en)
|
2022-06-08 |
2023-12-14 |
Research Instiitute At Nationwide Children's Hospital |
Products and methods for treating diseases or conditions associated with mutant or pathogenic kcnq3 expression
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024011115A1
(en)
|
2022-07-06 |
2024-01-11 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery of cln1 polynucleotide
|
WO2024035782A1
(en)
|
2022-08-10 |
2024-02-15 |
Aav Gene Therapeutics, Inc. |
Aav-mediated intramuscular delivery of insulin
|
WO2024081706A1
(en)
|
2022-10-11 |
2024-04-18 |
Research Institute At Nationwide Children's Hospital |
Adeno-associated virus delivery to treat spinal muscular atrophy with respiratory distress type 1 (smard1) and charcot-marie-tooth type 2s (cmt2s)
|
WO2024092126A1
(en)
|
2022-10-27 |
2024-05-02 |
Cargo Therapeutics, Inc. |
Compositions and methods for improved immunotherapies
|
WO2024129743A2
(en)
|
2022-12-13 |
2024-06-20 |
Bluerock Therapeutics Lp |
Engineered type v rna programmable endonucleases and their uses
|